Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.
Iurisci
Ida
I
Rich
Tyvin
T
Lévi
Francis
F
Innominato
Pasquale F
PF
Tinari
Nicola
N
Irtelli
Luciana
L
De Tursi
Michele
M
Grassadonia
Antonino
A
Iacobelli
Stefano
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D002940:Circadian Rhythm; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D011788:Quality of Life; D011799:Quinazolines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib